Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
|
|
DiaMedica Therapeutics Inc. (DMAC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
8-K
| Quarterly results |
| 05/18/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/15/2023 |
8-K
| Quarterly results |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/10/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/06/2023 |
8-K
| Resignation/termination of a director |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/26/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 07/06/2022 |
8-K
| Quarterly results |
| 06/29/2022 |
8-K
| Quarterly results |
| 05/25/2022 |
8-K
| Quarterly results |
| 05/19/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
8-K
| Quarterly results |
| 03/14/2022 |
8-K
| Quarterly results |
| 02/11/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results |
| 09/27/2021 |
8-K
| Quarterly results |
| 09/13/2021 |
8-K
| Quarterly results |
| 08/11/2021 |
8-K
| Quarterly results |
| 07/16/2021 |
8-K
| Quarterly results |
| 06/29/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
8-K
| Quarterly results |
| 04/29/2021 |
8-K
| Other Events |
| 03/10/2021 |
8-K
| Quarterly results |
| 11/04/2020 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"DiaMedica Therapeutics Inc. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Operating expenses: Research and development $ 2,180 $ 1,617 $ 5,190 $ 6,098 General and administrative 1,139 1,044 3,241 2,725 Operating loss Other expense: Governmental assistance - research incentives Other expense, net 38 Total other income Loss before income tax expense Income tax expense 2 12 20 29 Net loss Other comprehensive income Unrealized gain on marketable securities 8 6 Net loss and comprehensive loss $ $ $ $ Basic and diluted net loss per share $ $ $ $ Weighted average shares outstanding – basic and diluted 16,689,074 12,006,874 14,652,749 11,981,233 DiaMedica Therapeutics Inc. Consolidated ..." |
|
| 08/11/2020 |
8-K
| Quarterly results |
| 08/07/2020 |
8-K
| Quarterly results |
| 08/05/2020 |
8-K
| Quarterly results |
| 06/03/2020 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events |
| 05/13/2020 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits|
Docs:
|
"DiaMedica Therapeutics Inc. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended March 31, 2020 2019 Operating expenses: Research and development $ 1,381 $ 2,607 General and administrative 1,023 814 Operating loss Other expense: Governmental assistance - research incentives Other expense, net 127 Total other expense 12 Loss before income tax expense Income tax expense 9 9 Net loss Other comprehensive income Unrealized gain on marketable securities 40 3 Net loss and comprehensive loss $ $ Basic and diluted net loss per share $ $ Weighted average shares outstanding – basic and diluted 13,107,725 11,956,874 DiaMedica Therapeutics Inc. Consolidated Balance Sheets ASSETS Current assets: Cash and cash equivalents $ 3,300 $ 3,883 Marketable securities 9,348 3,995 ...",
"Investor Contact",
"Investor Presentation issued by DiaMedica Therapeutics, Inc. in connection with the release of its top-line results of its Phase II ReMEDy trial (furnished herewith)" |
|
| 03/23/2020 |
8-K
| Quarterly results |
| 02/13/2020 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits |
|
|
|